{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:31:33Z","timestamp":1793655093159,"version":"4.5.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.annonc.2024.08.2242","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T08:48:50Z","timestamp":1726303730000},"page":"968-980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"T.","family":"Van Gorp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Backes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Orta\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bodnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-P.","family":"Barretina-Ginesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Buchanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.C.","family":"Hanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Eminowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Rob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Lichfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2024.08.2242_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2024.08.2242_bib2","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3389\/fonc.2019.01440","article-title":"Global, regional, and national burden of endometrial cancer, 1990-2017: results from the Global Burden of Disease Study, 2017","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2024.08.2242_bib3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.08.2242_bib4","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Uterine Neoplasms. Version 2. 2024. Plymouth Meeting, PA, USA: NCCN. Available at https:\/\/www.nccn.org. Accessed March 6, 2024."},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2242_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2242_bib6","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2242_bib7","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.annonc.2024.08.2242_bib8","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1470-2045(19)30395-X","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial","volume":"20","author":"de Boer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1016\/j.annonc.2024.08.2242_bib9","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa1813181","article-title":"Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer","volume":"380","author":"Matei","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2024.08.2242_bib10","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1200\/JCO.21.01874","article-title":"Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study","volume":"40","author":"O'Malley","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"10.1016\/j.annonc.2024.08.2242_bib11","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2242_bib12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.annonc.2024.08.2242_bib13","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1200\/JCO.22.02152","article-title":"Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: updated efficacy and safety from the randomized phase III study 309\/KEYNOTE-775","volume":"41","author":"Makker","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2024.08.2242_bib14","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.annonc.2024.08.2242_bib15","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2024.08.2242_bib16","doi-asserted-by":"crossref","first-page":"S1281","DOI":"10.1016\/j.annonc.2023.10.034","article-title":"Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced\/recurrent endometrial carcinoma","volume":"34","author":"Colombo","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2242_bib17","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2242_bib18","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.08.2242_bib19","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdw542","article-title":"Practical guidance for mismatch repair-deficiency testing in endometrial cancer","volume":"28","author":"Stelloo","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2024.08.2242_bib20","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2024.08.2242_bib21","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2024.08.2242_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.crimmu.2023.100068","article-title":"Role of chemotherapeutic drugs in immunomodulation of cancer","volume":"4","author":"Mukherjee","year":"2023","journal-title":"Curr Res Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2024.08.2242_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2242_bib24","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2242_bib25","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.08.2242_bib26","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.08.2242_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.ygyno.2021.02.015","article-title":"Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer","volume":"161","author":"Da Cruz Paula","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.08.2242_bib28","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/path.6012","article-title":"The association between the tumor immune microenvironments and clinical outcome in low-grade, early-stage endometrial cancer patients","volume":"258","author":"Lopez-Janeiro","year":"2022","journal-title":"J\u00a0Pathol"},{"issue":"29","key":"10.1016\/j.annonc.2024.08.2242_bib29","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Leon-Castillo","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2242_bib30","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ygyno.2023.01.025","article-title":"Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer","volume":"170","author":"Jamieson","year":"2023","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.08.2242_bib31","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2024.08.2242_bib32","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.3390\/biomedicines9101385","article-title":"Long-term survival and clinicopathological implications of DNA mismatch repair status in endometrioid endometrial cancers in Hong Kong Chinese women","volume":"9","author":"Lee","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2242_bib33","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cncr.31901","article-title":"Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: a prognostic biomarker","volume":"125","author":"Backes","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2024.08.2242_bib34","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.3802\/jgo.2018.29.e39","article-title":"Endometrial cancer risk and survival by tumor MMR status","volume":"29","author":"Nagle","year":"2018","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.annonc.2024.08.2242_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5633","article-title":"The RAINBO MMRd-GREEN trial (GCIG\/DGOG\/ENGOT-EN142): a phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer","volume":"41","author":"Kaya","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.08.2242_bib38","doi-asserted-by":"crossref","unstructured":"Clements AE, Enserro D, Strickland C, et\u00a0al. Overall survival among patients in GOG-0258 by molecular classification with a modified ProMisE algorithm: ancillary analysis of GOG-0258. Paper presented at the Society of Gynecologic Oncology. 2024; San Diego, California.","DOI":"10.1016\/j.ygyno.2024.07.095"},{"key":"10.1016\/j.annonc.2024.08.2242_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.113530","article-title":"Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients","volume":"199","author":"Brahmer","year":"2024","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424038225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424038225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:14:51Z","timestamp":1732277691000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424038225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0923753424038225"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2242","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ENGOT-en11\/GOG-3053\/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s).  Published by Elsevier Ltd. On behalf of European Society for Medical Oncology","name":"copyright","label":"Copyright"}]}}